| Assay ID | Title | Year | Journal | Article |
|---|
| AID737517 | Inhibition of EGFR L858R mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737205 | Inhibition of PKA (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737476 | Inhibition of HIPK1(unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737252 | Inhibition of MAPKAPK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737214 | Inhibition of PASK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741247 | Inhibition of EGFR L861Q mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740730 | Inhibition of PRKG1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740767 | Inhibition of NEK6 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740783 | Inhibition of MRCKbeta (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741515 | Inhibition of TAO1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737474 | Inhibition of HCK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740772 | Inhibition of MET (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740764 | Inhibition of PAK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741537 | Inhibition of PRKX (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740458 | Inhibition of p38alpha (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740498 | Inhibition of ROCK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741056 | Inhibition of EPHB1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1916669 | Inhibition of mTORC2 (unknown origin) | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021). |
| AID741031 | Inhibition of GRK6 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741255 | Inhibition of DCAMKL2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737469 | Inhibition of IKK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741561 | Inhibition of PKCbeta2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741287 | Inhibition of BRK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740464 | Inhibition of cKit (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737993 | In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of S6 phosphorylation at 30 mg/kg, po qd measured at 24 hrs relative to vehicle-treated control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741496 | Inhibition of p38alpha (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741292 | Inhibition of Aurora B (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737472 | Inhibition of IGF-1R (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737471 | Inhibition of IKKbeta (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737263 | Inhibition of JNK3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741010 | Inhibition of JAK3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741556 | Inhibition of PKCiota (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737467 | Inhibition of IRAK4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740479 | Inhibition of STK25 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740485 | Inhibition of SGK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741521 | Inhibition of SNF1LK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737494 | Inhibition of FER (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741525 | Inhibition of RSK4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740991 | Inhibition of MARK4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737261 | Inhibition of KHS1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741251 | Inhibition of DYRK4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230522 | Ratio of drug uptake in human PC3 cells xenografted in mouse at 100 mg/kg, po measured after 2 hrs to IC50 for mTORC1 in human PC3 cells assessed as inhibition of S6 phosphorylation | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID1230521 | In vivo inhibition of mTORC1 in human PC3 cells xenografted in mouse assessed as inhibition of S6 phosphorylation at 100 mg/kg, po measured after 2 hrs relative to control | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID737530 | Inhibition of CAMK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737268 | Inhibition of JAK2-JH1-JH2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740724 | Inhibition of PIM2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740780 | Inhibition of MST1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741043 | Inhibition of FES (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230531 | Ratio of drug uptake in human PC3 cells xenografted in mouse at 100 mg/kg, po measured after 24 hrs to IC50 for mTORC1 in human PC3 cells assessed as inhibition of S6 phosphorylation | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID741044 | Inhibition of FER (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740488 | Inhibition of RSK3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740484 | Inhibition of SGK3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741303 | Inhibition of p38gamma (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737752 | Inhibition of ABL T315I mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740466 | Inhibition of ZIPK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741547 | Inhibition of PRKG2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740774 | Inhibition of MER (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741284 | Inhibition of BMX (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740744 | Inhibition of PKCbeta2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741266 | Inhibition of CLK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741280 | Inhibition of CDK5/p35 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737527 | Inhibition of CAMK2beta (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741551 | Inhibition of PKD3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741502 | Inhibition of cKit (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737250 | Inhibition of MARK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1916702 | Inhibition of PI3Kalpha (unknown origin) | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021). |
| AID740752 | Inhibition of PI3Kalpha (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740769 | Inhibition of NEK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740474 | Inhibition of TSSK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737728 | Inhibition of CK1delta (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741557 | Inhibition of PKCgamma (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737217 | Inhibition of PAK4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737751 | Inhibition of ABL Y253F mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737999 | Antitumor activity against human PC3 cells xenografted in po dosed CB17 SCID mouse assessed as tumor growth inhibition administered on day 11 post tumor implantation measured after 32 days relative to vehicle-treated control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737727 | Inhibition of CK1gamma2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740996 | Inhibition of MAPKAPK3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738005 | Antitumor activity against human PC3 cells xenografted in CB17 SCID mouse assessed as tumor growth inhibition at 20 mg/kg, po bid administered on day 11 post tumor implantation measured after 32 days | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741501 | Inhibition of cKit T670I mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737241 | Inhibition of MKK6 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741055 | Inhibition of EPHB2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737480 | Inhibition of GRK7 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741002 | Inhibition of LYNB (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741257 | Inhibition of CAMK4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740473 | Inhibition of TIE2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741512 | Inhibition of TSSK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740756 | Inhibition of PDGFRalpha T674I mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737493 | Inhibition of FES (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737525 | Inhibition of DAPK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737262 | Inhibition of KDR (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741507 | Inhibition of TYK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737731 | Inhibition of CK1alpha1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1916668 | Inhibition of mTORC1 (unknown origin) | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021). |
| AID740759 | Inhibition of PASK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741299 | Inhibition of ABL (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737249 | Inhibition of MARK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740454 | Inhibition of p70S6K (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737224 | Inhibition of NEK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741511 | Inhibition of TIE2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741528 | Inhibition of RSK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737269 | Inhibition of JAK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737780 | Plasma concentration in CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 24 hrs | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737491 | Inhibition of FLT1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740490 | Inhibition of RSK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737220 | Inhibition of NEK9 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740777 | Inhibition of MST3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740998 | Inhibition of MAPK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737270 | Inhibition of JAK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740993 | Inhibition of MARK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230518 | AUC (0 to infinity) in rat at 5 mg/kg, po | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID740776 | Inhibition of MST4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741035 | Inhibition of GRK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740988 | Inhibition of MEK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737501 | Inhibition of ERBB4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737235 | Inhibition of MSSK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737998 | Toxicity in CB17 SCID mouse xenografted with human PC3 cells at 10 to 50 mg/kg, po qd administered on day 11 post tumor implantation measured after 32 days | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737222 | Inhibition of NEK6 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737208 | Inhibition of PDK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737730 | Inhibition of CHK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740482 | Inhibition of SRMS (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737772 | Drug uptake in tumor of CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 24 hrs | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741009 | Inhibition of JNK1alpha1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737783 | Plasma concentration in CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 2 hrs | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737486 | Inhibition of GRK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737210 | Inhibition of PDGFRalpha V561D mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741514 | Inhibition of TBK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737502 | Inhibition of ERBB2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741046 | Inhibition of FGFR3 K650E mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740733 | Inhibition of PRAK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737473 | Inhibition of HGK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741264 | Inhibition of CLK3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738010 | Cytotoxicity against human PC3 cells assessed as growth inhibition after 3 days by WST1 assay | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737992 | In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of AKTS473 phosphorylation at 30 mg/kg, po qd after 2 to 8 hrs relative to vehicle-treated control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740487 | Inhibition of RSK4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741304 | Inhibition of p38beta (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740725 | Inhibition of PIM1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740770 | Inhibition of NEK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737238 | Inhibition of MRCKbeta (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737735 | Inhibition of CDK7/cyclin H/MAT1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737203 | Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737749 | Inhibition of ARG (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738015 | Inhibition of ALK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741253 | Inhibition of DYRK1B (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737511 | Inhibition of EPHA2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741297 | Inhibition of ABL G250E mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741281 | Inhibition of CDK2/cyclin A (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741012 | Inhibition of JAK2-JH1-JH2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740771 | Inhibition of MUSK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741240 | Inhibition of EPHA5 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741047 | Inhibition of FGFR3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737529 | Inhibition of CAMK2alpha (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741500 | Inhibition of cSRC (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741562 | Inhibition of PKCbeta1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741273 | Inhibition of CK1epsilon (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738002 | Antitumor activity against human PC3 cells xenografted in CB17 SCID mouse assessed as tumor growth inhibition at 10 mg/kg, po qd administered on day 11 post tumor implantation measured after 32 days relative to vehicle-treated control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741242 | Inhibition of EPHA3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230505 | Inhibition of PI3K-alpha (unknown origin) by mobility shift assay | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID741271 | Inhibition of CK1gamma1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741529 | Inhibition of RSE (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741029 | Inhibition of GSK3alpha (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737477 | Inhibition of GCK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741022 | Inhibition of IGF-1R (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740456 | Inhibition of p38delta (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741520 | Inhibition of SRMS (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737771 | Ratio of drug level in CB17 SCID mouse plasma xenografted with human PC3 cells at 30 mg/kg, po qd at 2 hrs to IC50 for mTORC2 in human PC3 cells | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737246 | Inhibition of MEK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737470 | Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740999 | Inhibition of MAP3K8 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738001 | Antitumor activity against human PC3 cells xenografted in CB17 SCID mouse assessed as tumor growth inhibition at 25 mg/kg, po qd administered on day 11 post tumor implantation measured after 32 days relative to vehicle-treated control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741249 | Inhibition of EGFR L858R mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737757 | Inhibition of ALK4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741555 | Inhibition of PKCmu (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737248 | Inhibition of MARK3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737738 | Inhibition of CDK1/cyclin B (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741259 | Inhibition of CAMK2delta (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230528 | In vivo inhibition of mTORC1 in human PC3 cells xenografted in mouse assessed as inhibition of S6 phosphorylation at 100 mg/kg, po measured after 24 hrs relative to control | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID1230508 | Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID740782 | Inhibition of MSK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741564 | Inhibition of PKBgamma (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737761 | Ratio of drug level in tumor of CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 8 hrs to IC50 for mTORC2 in human PC3 cells | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737737 | Inhibition of CDK2/cyclin A (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741254 | Inhibition of DYR1A (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737481 | Inhibition of GRK6 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741245 | Inhibition of EGFR T790M/L858R double mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737266 | Inhibition of JAK3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740784 | Inhibition of MRCKalpha (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737509 | Inhibition of EPHA4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740457 | Inhibition of p38beta (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737740 | Inhibition of BLK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737764 | Ratio of free drug level in CB17 SCID mouse plasma xenografted with human PC3 cells at 30 mg/kg, po qd at 24 hrs to IC50 for mTORC2 in human PC3 cells | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740748 | Inhibition of PKBgamma (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741300 | Inhibition of AMPK A2/B1/G1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741051 | Inhibition of ERBB4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741298 | Inhibition of ABL E255K mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737519 | Inhibition of DYRK4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741006 | Inhibition of KDR (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737734 | Inhibition of CDK5/p35 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741523 | Inhibition of SGK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740781 | Inhibition of MSK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737504 | Inhibition of EPHB3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741543 | Inhibition of PHKgamma2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737488 | Inhibition of FLT4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737724 | Inhibition of CK1gamma3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737484 | Inhibition of GRK3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737503 | Inhibition of EPHB4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737512 | Inhibition of EPHA1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738003 | Antitumor activity against human PC3 cells xenografted in CB17 SCID mouse assessed as tumor growth inhibition at 100 mg/kg, po administered on day 11 for every two days post tumor implantation measured after 32 days | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737997 | In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of S6 phosphorylation at 100 mg/kg, po qd after 24 hrs | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737487 | Inhibition of FMS (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741544 | Inhibition of PHKgamma1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741294 | Inhibition of ARG (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737743 | Inhibition of BRK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740477 | Inhibition of TAO1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741527 | Inhibition of RSK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737498 | Inhibition of FGFR2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741539 | Inhibition of PLK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230537 | Ratio of drug uptake in human PC3 cells xenografted in mouse at 100 mg/kg, po measured after 24 hrs to IC50 for mTORC2 in human PC3 cells assessed as inhibition of Akt phosphorylation at S473 | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID737744 | Inhibition of BRAF V599E mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737227 | Inhibition of MET M1250T mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740723 | Inhibition of PLK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738011 | Inhibition of mTORC2 in human PC3 cells assessed as inhibition of AKTS473 phosphorylation after 1 hr by sandwich immunoassay | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741559 | Inhibition of PKCepsilon (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741282 | Inhibition of CDK1/cyclin B (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740729 | Inhibition of PTK2B (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737489 | Inhibition of FLT3 D835Y mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737209 | Inhibition of PDGFR beta (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741531 | Inhibition of RON (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737478 | Inhibition of GSK3beta (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230533 | In vivo inhibition of mTORC1 in human PC3 cells xenografted in mouse assessed as inhibition of Akt phosphorylation at S473 at 100 mg/kg, po measured after 8 hrs relative to control | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID737768 | Ratio of drug level in CB17 SCID mouse plasma xenografted with human PC3 cells at 30 mg/kg, po qd at 8 hrs to IC50 for mTORC2 in human PC3 cells | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737221 | Inhibition of NEK7 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740788 | Inhibition of MELK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230535 | Ratio of drug uptake in human PC3 cells xenografted in mouse at 100 mg/kg, po measured after 2 hrs to IC50 for mTORC2 in human PC3 cells assessed as inhibition of Akt phosphorylation at S473 | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID737506 | Inhibition of EPHB1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737748 | Inhibition of Aurora B (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737532 | Inhibition of CLK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741020 | Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737242 | Inhibition of MINK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741295 | Inhibition of ABL Y253F mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737750 | Inhibition of Aurora A (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737786 | Cmax in rat at 5 mg/kg, po | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740731 | Inhibition of PRKG2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741283 | Inhibition of BRSK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740459 | Inhibition of mTOR (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737996 | In vivo inhibition of mTORC2 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of AKTS473 phosphorylation at 100 mg/kg, po qd after 24 hrs | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737784 | Tmax in rat at 5 mg/kg, po | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737490 | Inhibition of FLT3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737739 | Inhibition of BRSK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741549 | Inhibition of PRK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737213 | Inhibition of PDGFRalpha (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737787 | Mean residence time in rat at 2 mg/kg, iv | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737260 | Inhibition of LRRK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741252 | Inhibition of DYRK3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740787 | Inhibition of MINK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741279 | Inhibition of CDK5/p25 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737778 | Free plasma concentration in CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 4 hrs | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737775 | Drug uptake in tumor of CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 4 hrs | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740753 | Inhibition of PDK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740722 | Inhibition of PLK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737495 | Inhibition of FGFR4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740470 | Inhibition of TRKC (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737745 | Inhibition of AXL (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741546 | Inhibition of PTK2B (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741007 | Inhibition of JNK3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737776 | Free plasma concentration in CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 8 hrs | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737497 | Inhibition of FGFR3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740735 | Inhibition of PKD2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737505 | Inhibition of EPHB2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737253 | Inhibition of MAPK3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740491 | Inhibition of RSE (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230527 | In vivo inhibition of mTORC1 in human PC3 cells xenografted in mouse assessed as inhibition of S6 phosphorylation at 100 mg/kg, po measured after 8 hrs relative to control | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID741011 | Inhibition of JAK2 JH1 JH2 V617F mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737721 | Inhibition of CLK3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740779 | Inhibition of MSSK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741258 | Inhibition of CAMK2beta (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737520 | Inhibition of DYRK3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737468 | Inhibition of IR (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741042 | Inhibition of FGR (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740471 | Inhibition of TRKB (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737226 | Inhibition of MUSK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740472 | Inhibition of TRKA (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741288 | Inhibition of BRAF V599E mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741005 | Inhibition of KHS1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737513 | Inhibition of EGFR T790M/L858R double mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741526 | Inhibition of RSK3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737215 | Inhibition of PAK7 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740739 | Inhibition of PKCmu (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737524 | Inhibition of CAMK4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741021 | Inhibition of IKKbeta (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741030 | Inhibition of GRK7 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737245 | Inhibition of MATK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741036 | Inhibition of FYN (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740741 | Inhibition of PKCepsilon (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741517 | Inhibition of STK25 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737747 | Inhibition of Aurora C (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737758 | Inhibition of AMPK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740997 | Inhibition of MAPK3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740467 | Inhibition of ZAP70 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737789 | Volume of distribution at steady state in rat at 2 mg/kg, iv | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740728 | Inhibition of PTK5 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741260 | Inhibition of CAMK1-delta (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738008 | Clearance in rat at 2 mg/kg, iv | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230509 | Metabolic stability in rat S9 fraction assessed as compound remaining measured at 60 mins | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID737763 | Ratio of drug level in tumor of CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 2 hrs to IC50 for mTORC2 in human PC3 cells | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740762 | Inhibition of PAK4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741017 | Inhibition of IRR (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741014 | Inhibition of ITK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230541 | Antitumor activity against human PC3 cells xenografted in mouse assessed as tumor growth inhibition at 50 mg/kg, po qd | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID741497 | Inhibition of mTOR (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737759 | Inhibition of ALK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737725 | Inhibition of CK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737254 | Inhibition of MAPK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741265 | Inhibition of CLK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740740 | Inhibition of PKCgamma (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740745 | Inhibition of PKCbeta1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737785 | AUC (0 to infinity) in rat at 5 mg/kg, po | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741028 | Inhibition of GSK3beta (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740738 | Inhibition of PKCiota (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737256 | Inhibition of LTK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737781 | Plasma concentration in CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 4 hrs | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741285 | Inhibition of BLK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740757 | Inhibition of PDGFRalpha D842V mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740742 | Inhibition of PKCeta (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740994 | Inhibition of MARK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230534 | In vivo inhibition of mTORC1 in human PC3 cells xenografted in mouse assessed as inhibition of Akt phosphorylation at S473 at 100 mg/kg, po measured after 24 hrs relative to control | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID737211 | Inhibition of PDGFRalpha T674I mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741016 | Inhibition of IRAK4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741026 | Inhibition of HIPK1(unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740495 | Inhibition of RET (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741262 | Inhibition of CSK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737483 | Inhibition of GRK4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740758 | Inhibition of PDGFRalpha (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741004 | Inhibition of LRRK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740755 | Inhibition of PDGFRalpha V561D mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741550 | Inhibition of PRAK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737206 | Inhibition of PI3Kgamma (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737492 | Inhibition of FGR (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737994 | In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of S6 phosphorylation at 30 mg/kg, po qd after 2 to 8 hrs relative to vehicle-treated control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741290 | Inhibition of AXL (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740468 | Inhibition of YES (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741301 | Inhibition of AMPK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740754 | Inhibition of PDGFR beta (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737767 | Ratio of free drug level in CB17 SCID mouse plasma xenografted with human PC3 cells at 30 mg/kg, po qd at 2 hrs to IC50 for mTORC2 in human PC3 cells | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740992 | Inhibition of MARK3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740493 | Inhibition of RON (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741037 | Inhibition of FMS (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741015 | Inhibition of JAK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737247 | Inhibition of MARK4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741291 | Inhibition of Aurora C (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737212 | Inhibition of PDGFRalpha D842V mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737755 | Inhibition of ABL (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740497 | Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740743 | Inhibition of PKCdelta (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230519 | Oral bioavailability in rat at 5 mg/kg | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID737479 | Inhibition of GSK3alpha (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741548 | Inhibition of PRKG1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737258 | Inhibition of LYNB (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741504 | Inhibition of c-RAF (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741532 | Inhibition of RET Y791F mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740761 | Inhibition of PAK6 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740463 | Inhibition of cKit T670I mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738012 | Inhibition of mTORC1 in human PC3 cells assessed as inhibition of S6 phosphorylation after 1 hr by sandwich immunoassay | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737765 | Ratio of free drug level in CB17 SCID mouse plasma xenografted with human PC3 cells at 30 mg/kg, po qd at 8 hrs to IC50 for mTORC2 in human PC3 cells | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741041 | Inhibition of FLT1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740494 | Inhibition of RET Y791F mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741563 | Inhibition of PKCalpha (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740778 | Inhibition of MST2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737729 | Inhibition of CK1epsilon (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741000 | Inhibition of LCK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741019 | Inhibition of IKK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737991 | In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of AKTS473 phosphorylation at 30 mg/kg, po qd measured at 24 hrs relative to vehicle-treated control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740476 | Inhibition of TBK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740720 | Inhibition of PRKX (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741505 | Inhibition of ZAP70 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740492 | Inhibition of ROS (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741510 | Inhibition of TRKA (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737723 | Inhibition of CK2 alpha2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741302 | Inhibition of p70S6K (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740786 | Inhibition of MKK6 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737742 | Inhibition of BTK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737508 | Inhibition of EPHA5 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741027 | Inhibition of GCK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738004 | Antitumor activity against human PC3 cells xenografted in CB17 SCID mouse assessed as tumor growth inhibition at 50 mg/kg, po qd administered on day 11 post tumor implantation measured after 32 days | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737265 | Inhibition of JNK1alpha1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737259 | Inhibition of LYNA (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741269 | Inhibition of CK1gamma2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740462 | Inhibition of cSRC (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738009 | Selectivity ratio of IC50 for PI3Kalpha (unknown origin) to IC50 for recombinant mTOR (unknown origin) | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741052 | Inhibition of ERBB2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740750 | Inhibition of PKA (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737255 | Inhibition of MAP3K8 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741018 | Inhibition of IR (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740763 | Inhibition of PAK3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741053 | Inhibition of EPHB4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741518 | Inhibition of SRPK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737244 | Inhibition of MEK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741513 | Inhibition of TSSK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737754 | Inhibition of ABL E255K mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230536 | Ratio of drug uptake in human PC3 cells xenografted in mouse at 100 mg/kg, po measured after 8 hrs to IC50 for mTORC2 in human PC3 cells assessed as inhibition of Akt phosphorylation at S473 | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID740768 | Inhibition of NEK4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741289 | Inhibition of BRAF (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737228 | Inhibition of MET (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741516 | Inhibition of SYK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741025 | Inhibition of HIPK4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741533 | Inhibition of RET V804L mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737485 | Inhibition of FYN (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741246 | Inhibition of EGFR T790M mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741534 | Inhibition of RET (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741261 | Inhibition of CAMK2alpha (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737515 | Inhibition of EGFR L861Q mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740746 | Inhibition of PKCalpha (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737240 | Inhibition of MLK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740727 | Inhibition of PHKgamma1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737482 | Inhibition of GRK5 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737782 | Plasma concentration in CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 8 hrs | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737518 | Inhibition of EEF2K (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741250 | Inhibition of EEF2K (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740751 | Inhibition of PI3Kgamma (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741558 | Inhibition of PKCeta (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741241 | Inhibition of EPHA4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741013 | Inhibition of JAK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1916683 | Inhibition of mTOR (unknown origin) | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021). |
| AID1230524 | In vivo inhibition of mTORC1 in human PC3 cells xenografted in mouse assessed as inhibition of Akt phosphorylation at S473 at 100 mg/kg, po measured after 2 hrs relative to control | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID737753 | Inhibition of ABL G250E mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738007 | Oral bioavailability in rat at 5 mg/kg | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740465 | Inhibition of c-RAF (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741272 | Inhibition of CK1delta (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740721 | Inhibition of PLK3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737243 | Inhibition of MELK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741001 | Inhibition of LTK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740775 | Inhibition of MYLK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737733 | Inhibition of CHK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741270 | Inhibition of CK1gamma3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741540 | Inhibition of PLK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737251 | Inhibition of MAPKAPK3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740455 | Inhibition of p38gamma (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737239 | Inhibition of MRCKalpha (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737762 | Ratio of drug level in tumor of CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 4 hrs to IC50 for mTORC2 in human PC3 cells | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740747 | Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737496 | Inhibition of FGFR3 K650E mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741305 | Inhibition of p38delta (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737756 | Inhibition of AMPK A2/B1/G1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737465 | Inhibition of ITK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738013 | Inhibition of PI3Kalpha (unknown origin) by mobility shift assay | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737229 | Inhibition of MER (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737995 | Plasma protein binding in CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd after 24 hrs | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740460 | Inhibition of cSRC N1 mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230530 | Ratio of drug uptake in human PC3 cells xenografted in mouse at 100 mg/kg, po measured after 8 hrs to IC50 for mTORC1 in human PC3 cells assessed as inhibition of S6 phosphorylation | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID1230544 | Antitumor activity against human PC3 cells xenografted in mouse assessed as tumor volume reduction at 50 mg/kg, po qd for 21 days relative to control | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID737774 | Drug uptake in tumor of CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 2 hrs | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741263 | Inhibition of CAMK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741552 | Inhibition of PKD2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741506 | Inhibition of YES (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741050 | Inhibition of FAK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230539 | Antitumor activity against human PC3 cells xenografted in po dosed mouse assessed as tumor growth inhibition administered as qd for 21 days | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID1230515 | Selectivity ratio of IC50 for PI3K-alpha (unknown origin) to IC50 for mTOR (unknown origin) | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID741048 | Inhibition of FGFR2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741524 | Inhibition of SGK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737514 | Inhibition of EGFR T790M mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737218 | Inhibition of PAK3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738016 | Inhibition of ALK4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741296 | Inhibition of ABL T315I mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741554 | Inhibition of PKCtheta (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741054 | Inhibition of EPHB3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741024 | Inhibition of HCK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741040 | Inhibition of FLT3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741293 | Inhibition of Aurora A (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740478 | Inhibition of SYK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230526 | In vivo inhibition of mTORC1 in human PC3 cells xenografted in mouse assessed as inhibition of S6 phosphorylation at 100 mg/kg, po measured after 4 hrs relative to control | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID737531 | Inhibition of CSK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741503 | Inhibition of ZIPK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741538 | Inhibition of PLK3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737233 | Inhibition of MST3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741542 | Inhibition of PIM1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737257 | Inhibition of LCK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741049 | Inhibition of FGFR1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741243 | Inhibition of EPHA2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740766 | Inhibition of NEK7 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741033 | Inhibition of GRK4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741509 | Inhibition of TRKB (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741278 | Inhibition of CDK7/cyclin H/MAT1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737773 | Drug uptake in tumor of CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 8 hrs | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741530 | Inhibition of ROS (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741286 | Inhibition of BTK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737788 | AUC (0 to infinity) in rat at 2 mg/kg, iv | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737769 | Ratio of drug level in CB17 SCID mouse plasma xenografted with human PC3 cells at 30 mg/kg, po qd at 24 hrs to IC50 for mTORC2 in human PC3 cells | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737741 | Inhibition of BMX (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737267 | Inhibition of JAK2 JH1 JH2 V617F mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741560 | Inhibition of PKCdelta (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737526 | Inhibition of CAMK2delta (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737232 | Inhibition of MST2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741256 | Inhibition of DAPK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741499 | Inhibition of IRRK2 G2019S mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737225 | Inhibition of NEK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740726 | Inhibition of PHKgamma2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737219 | Inhibition of PAK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738006 | Inhibition of FMS (unknown origin) | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737766 | Ratio of free drug level in CB17 SCID mouse plasma xenografted with human PC3 cells at 30 mg/kg, po qd at 4 hrs to IC50 for mTORC2 in human PC3 cells | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740995 | Inhibition of MAPKAPK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741535 | Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740732 | Inhibition of PRK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740990 | Inhibition of MATK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741244 | Inhibition of EPHA1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737507 | Inhibition of EPHA8 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740489 | Inhibition of RSK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737237 | Inhibition of MSK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737236 | Inhibition of MSK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740734 | Inhibition of PKD3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741277 | Inhibition of CHK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737779 | Free plasma concentration in CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 2 hrs | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741545 | Inhibition of PTK5 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737521 | Inhibition of DYR1A (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737746 | Inhibition of BRAF (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737516 | Inhibition of EGFR (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740496 | Inhibition of RET V804L mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737231 | Inhibition of MST4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741034 | Inhibition of GRK3 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737760 | Ratio of drug level in tumor of CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 24 hrs to IC50 for mTORC2 in human PC3 cells | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738000 | Antitumor activity against human PC3 cells xenografted in CB17 SCID mouse assessed as tumor growth inhibition at 50 mg/kg, po qd administered on day 11 post tumor implantation measured after 32 days relative to vehicle-treated control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740475 | Inhibition of TSSK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741039 | Inhibition of FLT3 D835Y mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741522 | Inhibition of SGK3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737207 | Inhibition of PI3Kalpha (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740737 | Inhibition of PKCtheta (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737732 | Inhibition of CDK9/cyclin T1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741023 | Inhibition of HGK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID738014 | Inhibition of recombinant mTOR (unknown origin) using GST-p70S6 as substrate after 60 mins by TR-FRET analysis | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230532 | In vivo inhibition of mTORC1 in human PC3 cells xenografted in mouse assessed as inhibition of Akt phosphorylation at S473 at 100 mg/kg, po measured after 4 hrs relative to control | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID741275 | Inhibition of CK1alpha1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737223 | Inhibition of NEK4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230516 | Cmax in rat at 5 mg/kg, po | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID737522 | Inhibition of DYRK1B (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740461 | Inhibition of IRRK2 G2019S mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741519 | Inhibition of SRPK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737234 | Inhibition of MST1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740736 | Inhibition of PKCzeta (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740480 | Inhibition of SRPK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230529 | Ratio of drug uptake in human PC3 cells xenografted in mouse at 100 mg/kg, po measured after 4 hrs to IC50 for mTORC1 in human PC3 cells assessed as inhibition of S6 phosphorylation | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID737475 | Inhibition of HIPK4 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737264 | Inhibition of JNK2alpha2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737722 | Inhibition of CLK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741248 | Inhibition of EGFR (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740773 | Inhibition of MET M1250T mutant (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741239 | Inhibition of EPHA8 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741032 | Inhibition of GRK5 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741267 | Inhibition of CK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230523 | Inhibition of mTORC2 in human PC3 cells assessed as inhibition of Akt phosphorylation at S473 after 1 hr | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID737736 | Inhibition of CDK5/p25 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740785 | Inhibition of MLK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740765 | Inhibition of NEK9 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741003 | Inhibition of LYNA (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741541 | Inhibition of PIM2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737466 | Inhibition of IRR (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741274 | Inhibition of CHK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737230 | Inhibition of MYLK2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230520 | Inhibition of mTORC1 in human PC3 cells assessed as inhibition of S6 phosphorylation after 1 hr | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID741508 | Inhibition of TRKC (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737499 | Inhibition of FGFR1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741498 | Inhibition of cSRC N1 mutant (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737528 | Inhibition of CAMK1-delta (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737770 | Ratio of drug level in CB17 SCID mouse plasma xenografted with human PC3 cells at 30 mg/kg, po qd at 4 hrs to IC50 for mTORC2 in human PC3 cells | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741268 | Inhibition of CK2 alpha2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740486 | Inhibition of SGK (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740469 | Inhibition of TYK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740749 | Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741008 | Inhibition of JNK2alpha2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741045 | Inhibition of FGFR4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737510 | Inhibition of EPHA3 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740989 | Inhibition of MEK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737204 | Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737523 | Inhibition of DCAMKL2 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230514 | Clearance in rat at 2 mg/kg, iv | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID741276 | Inhibition of CDK9/cyclin T1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741038 | Inhibition of FLT4 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737216 | Inhibition of PAK6 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737500 | Inhibition of FAK (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740483 | Inhibition of SNF1LK2 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737726 | Inhibition of CK1gamma1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID1230525 | Ratio of drug uptake in human PC3 cells xenografted in mouse at 100 mg/kg, po measured after 4 hrs to IC50 for mTORC2 in human PC3 cells assessed as inhibition of Akt phosphorylation at S473 | 2015 | Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
| Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. |
| AID740760 | Inhibition of PAK7 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID737777 | Free plasma concentration in CB17 SCID mouse xenografted with human PC3 cells at 30 mg/kg, po qd at 24 hrs | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741536 | Inhibition of ROCK1 (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID741553 | Inhibition of PKCzeta (unknown origin) assessed as remaining activity at 10 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| AID740481 | Inhibition of SRPK1 (unknown origin) assessed as remaining activity at 1 uM relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |